Business Context and Reporting Period
Hercules Capital, Inc. (HTGC) is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and taxed as a Regulated Investment Company (RIC). The company focuses on providing senior secured loans to high-growth, venture capital-backed technology and life sciences companies. This summary covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (Three Months) | Q3 2024 (Three Months) | YTD 2025 (Nine Months) | YTD 2024 (Nine Months) |
|---|---|---|---|---|
| Total Investment Income | $138.1 million | $125.2 million | $395.1 million | $371.8 million |
| Net Investment Income | $88.6 million | $83.2 million | $254.7 million | $244.7 million |
| Net Realized Gain (Loss) | ($1.9 million) | ($0.6 million) | ($61.0 million) | $1.8 million |
| Net Change in Unrealized Appreciation | $33.0 million | ($13.9 million) | $55.2 million | ($45.0 million) |
| Net Increase in Net Assets from Operations | $119.7 million | $68.7 million | $248.9 million | $201.5 million |
| Net Asset Value (NAV) per Share | $12.05 | $11.40 | $12.05 | $11.40 |
| Total Debt Outstanding | $2.18 billion | $1.78 billion | $2.18 billion | $1.78 billion |
| Weighted Average Cost of Debt | 5.1% | 5.1% | 4.9% | 5.0% |
| Portfolio Turnover Rate (YTD) | 19.01% (2025) vs 20.06% (2024) |
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio fair value increased to $4.31 billion as of September 30, 2025, from $3.66 billion at December 31, 2024. This growth was driven by net debt fundings of $1.33 billion and equity fundings of $10.4 million during the nine-month period.
- Realized Losses: The company recognized a net realized loss of $61.0 million for the nine months ended September 30, 2025, compared to a gain of $1.8 million in the prior year. This was primarily due to write-offs of debt investments (Khoros, LLC and Annex Cloud) and equity/warrant investments (HilleVax, Inc., bluebird bio, Inc.) offset by gains from warrant collections.
- Unrealized Appreciation: A significant shift occurred from net unrealized depreciation in the prior year to net unrealized appreciation of $55.2 million YTD 2025. This was driven by tightening credit spreads on debt investments and appreciation in public equity and warrant holdings.
- Debt Structure: The company issued $287.5 million in 2028 Convertible Notes and $350.0 million in June 2030 Notes. It also fully repaid $170 million in maturing notes (February, June, and June 3-Year Notes) during the period.
- Expense Allocation: Expenses allocated to the Adviser Subsidiary increased to $10.8 million YTD 2025 from $7.9 million in the prior year, reflecting increased time spent by senior management on Adviser Funds.
Guidance, Outlook, and Risks
- Dividend Policy: The Board declared a quarterly distribution of $0.40 per share plus a supplemental distribution of $0.07 per share for the quarter ended September 30, 2025. The company maintains a policy of distributing substantially all taxable income.
- Liquidity: As of September 30, 2025, available liquidity totaled approximately $655 million, including cash and available borrowing capacity under credit facilities (SMBC and MUFG). The company has accordion provisions allowing for an additional $360 million in borrowing capacity.
- Portfolio Yield: The weighted average core yield on debt investments was 12.5% for the quarter, down from 13.3% in the prior year quarter, while the effective yield was 13.5%.
- Risk Factors:
- Concentration Risk: Seven portfolio companies represented greater than 5% of net assets, including Phathom Pharmaceuticals, Marathon Health, and Armis, Inc.
- Interest Rate Risk: Approximately 97.8% of the debt portfolio is floating-rate with floors, providing some insulation against rate declines but exposing the company to cost increases if rates rise significantly.
- Valuation Risk: Approximately 97.6% of total assets are Level 3 investments valued using significant unobservable inputs, making fair value estimates sensitive to changes in hypothetical market yields.
Investor Verification Checklist
- Verify the specific portfolio companies contributing to the $61 million net realized loss to assess credit quality trends.
- Review the "Unfunded Commitments" table ($437.5 million) to understand future capital deployment obligations.
- Monitor the "Non-accrual" investment balance ($52 million or 1.2% of portfolio) for signs of deteriorating credit performance.
- Confirm the status of the 2028 Convertible Notes conversion rate and potential dilution impact.
- Check the "Control Investments" schedule for performance of majority-owned subsidiaries like Gibraltar Acquisition LLC and Hercules Adviser LLC.